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Abstract 
Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory 
disease. Provided that steroids represent the gold standard as a first line treatment, many immune suppressants 
drugs are currently used in the disease management. However, refractory disease is still a great challenge. Rituximab 
is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic 
autoimmune diseases. There are few case reports describing the successful use of Rituximab in refractory sarcoidosis 
with lung, eye, lymph nodes and skin involvement. In this paper we described three different case reports in which 
Rituximab has been used to treat refractory sarcoidosis and we reviewed the existing literature.
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Background
Sarcoidosis is a granulomatous disease whose outcome is 
quite variable. Most patients undergo spontaneous reso-
lution or present a good response to systemic treatment, 
but a small percentage of patients develop a chronic, 
progressive disease, which can be refractory to multiple 
lines of treatment [1]. Provided that steroids represent 
the gold standard as first line treatment, immunosup-
pressive drugs and antimalarial therapies are currently 
used in the clinical management of the disease, when 
steroid-dependence or resistance develop. Over the last 
few years, anti-TNFα agents have become a therapeutic 
option in refractory sarcoidosis [2]. However, there is still 
need for further options for those patients whose disease 
fail to respond to the above mentioned drugs.
Despite being a T cell mediated disease [3], humoral 
mechanisms might play a role in the pathogenesis of 
sarcoidosis [4]; moreover, B-cell-targeted therapies have 
been successfully used in autoimmune disorders in which 
T cells has been demonstrated to have a prominent 
pathogenetic role [5, 6].
Rituximab is an anti-CD20 chimeric monoclonal anti-
body, currently used for the treatment of B cell malignan-
cies and immune-mediated diseases such as rheumatoid 
arthritis and ANCA-associated vasculitides [7–10]. Few 
case reports and a retrospective study suggested the 
effectiveness of rituximab in the management of refrac-
tory sarcoidosis [11–15]. A prospective phase I/II trial 
has also been published investigating the role of rituxi-
mab in the treatment of refractory pulmonary sarcoidosis 
[16].
Herein we describe the impact of Rituximab in three 
diverse cases of refractory sarcoidosis with different 
organs involvement and we review the currently available 
evidence regarding the use of the anti-CD20 monoclonal 




A 35  years old Caucasian male presenting painful bilat-
eral enlargement of inguinal lymph nodes and progressive 
dyspnoea underwent node biopsy, allowing a histologic 
diagnosis of sarcoidosis. A chest X-ray was consistent 
with a stage 2 sarcoidosis according to Scadding classi-
fication (mediastinal lymphadenopathy and interstitial 
pulmonary involvement), confirmed by a subsequent CT 
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scan, also revealing abdominal lymphadenopathy. Pulmo-
nary function tests showed a mild restrictive disease and 
a moderate reduction in DLco value; bronchoalveolar 
lavage fluid analysis demonstrated increased number of 
lymphocytes and a high CD4/CD8 T-lymphocytes ratio. 
Ophthalmologic evaluation was unremarkable and no 
skin lesions were detected.
Due to symptomatic pulmonary involvement, patient 
was initially treated with corticosteroids, starting with 
prednisone 30 mg/day (0.5 mg/kg of body weight) in June 
2008, progressively tapered until 5 mg/day in September 
2009. CT scan and pulmonary function tests both dis-
played an improvement after therapy, with normalization 
of lymph nodes size, recovery of interstitial pulmonary 
disease and increase of FVC with remission of dyspnoea; 
DLco was stable. Unfortunately, patient remained ster-
oid-dependent and, early in 2010, developed a recrudes-
cence of dyspnoea. Therapy with methotrexate (10  mg/
week) was therefore started, obtaining a new remission 
of symptoms. 6 months later patient was asymptomatic; 
CT scan only revealed mild fibrotic scars interesting the 
upper lobes and pulmonary function tests were normal, 
with exception of a slight DLco decline. Thus, methotrex-
ate was progressively tapered and stopped in 6  months 
time.
Eight months later patient complained of a new wors-
ening of dyspnoea and a CT scan showed an interstitial 
pulmonary involvement, prevalent in the upper lobes, 
with recurrence of lymphadenopathy. Azathioprine was 
started and suspended in few weeks, due to intoler-
ance. Cyclophosphamide was then administered every 
2  weeks in our outpatient clinic for 6 times; the initial 
dose was 600 mg, later escalated up to 750 mg. A chest 
CT scan performed at the end of the treatment showed 
no progression of the disease, but a new assessment 
after 6 months revealed new radiological signs of active 
interstitial lung disease, extending from upper to lower 
lobes, with increasing evidence of parenchymal and peri-
bronchial fibrosis. A worsening was registered in terms 
of dyspnoea and lung function (Fig.  1). Patient refused 
infliximab as a treatment option, due to the long term 
administration schedule. Thus, rituximab 375  mg/m2 
every 2 weeks for six times was administered. Treatment 
was well tolerated and three further evaluations, respec-
tively 6, 12 and 18 months after the end of the treatment, 
highlighted an arrest in lung disease progression. At pre-
sent patient only has radiological evidence of inactive 
fibrotic lesions, prevalently located at upper lobes, and a 
stable restrictive disease (Fig. 1); he is under maintenance 
treatment with hydroxychloroquine.
Case 2
Patient 2 was referred to our outpatient clinic in June 2013, 
due to chronic sarcoidosis refractory to standard therapy. 
He was a North-African 44  years old man, employed in 
a tannery. The past medical history included papillary 
breast cancer, hypertension (treated with calcium chan-
nel blockers) and paroxysmal atrial fibrillation. The breast 
cancer was diagnosed in January 2008 and treated with 
radical mastectomy and subsequent hormone therapy with 
tamoxifene up to March 2013, when last oncologic evalua-
tion showed no evidence of relapse after 5 years. Serologic 
tests indicated a previous HBV infection.
The first report of granulomatous disease was dated at 
the time of mastectomy, when histological examination 
of sentinel lymph nodes resulted negative for cancer infil-
tration, but described the presence of a granulomatous 
reaction. A chest X-ray then showed bilateral mediasti-
nal enlargement, with no metabolic activity at a 18F-FDG 
PET/CT scan. At that time patient was asymptomatic 
and a follow-up plan was started as for an asymptomatic 
stage 2 sarcoidosis.
One year later, in 2009, inguinal lymph node enlarge-
ment became clinically evident, and a PET/CT scan 
showed marked FDG uptake in mediastinal, carenal, 
axillary and inguinal lymph nodes. A cutaneous lesion 
appeared involving the nose, classified as lupus pernio. 
Nodal and cutaneous biopsies showed non-necrotizing 
granulomatous inflammation, consistent with sarcoidosis. 
Patient did not present systemic symptoms at that time 
point. Specific therapy for sarcoidosis was then started, 
but clinical signs of the disease did not improve after cor-
ticosteroid treatment (prednisone) not even when asso-
ciated to azathioprine. The patient, conversely, started 
complaining of fever and cough and azathioprine was 
replaced by methotrexate and high dose steroids (1  mg/
kg, then tapered), with initial benefit but recurrence of 
Fig. 1 Lung volumes and DLco in patient 1.
Page 3 of 5Cinetto et al. Clin Mol Allergy  (2015) 13:19 
systemic symptoms when tapering the steroids below 
10 mg/die. A PET-CT scan (April 2013) was superimpos-
able to the previous one, in terms of lymph nodes involve-
ment, but showing an increased metabolic activity.
Due to the refractoriness of his disease, with a high-
dose steroid dependence and persistence of systemic 
symptoms (fever, fatigue, cough, dyspnoea on exertion) 
the patient was at this point referred to our outpatient 
clinic. Physical examination was normal, except for the 
presence of lupus pernio and one cutaneous lesion on the 
forehead. ACE levels were normal. Pulmonary function 
tests showed a slight reduction of lung volumes with nor-
mal flow rates; diffusion of CO was reduced (67%).
Given the recent anamnestic malignancy and after dis-
cussion with the Oncologists, we decided to avoid anti-
TNF drugs and to start a treatment with Rituximab at 
the dose of 1 g per month (this schedule was necessary 
to match patient’s travel needs). Hydroxychloroquine 
was started as a co-treatment, progressively tapering 
the prednisone. After 3 monthly infusions, symptoms 
improved despite the complete steroids withdrawal: 
fever disappeared, cutaneous lesions were significantly 
reduced compared to baseline, and only a slight dysp-
nea during exercise persisted. Pulmonary function tests 
and a PET-CT scan were superimposable to the tests 
performed before Rituximab; ACE levels were abnor-
mally increased. 4  months after the last dose systemic 
symptoms recurred, associated with exacerbation of 
the cutaneous lesions. Three monthly administrations 
of Rituximab were repeated, followed by a maintenance 
treatment with mycophenolate mofetil. During this sec-
ond course of treatment, we observed only a slight and 
temporary improvement in cutaneous lesions.
At present, after 8 months of therapy with mycopheno-
late mofetil, the clinical picture is worsening: the patient 
is still complaining of fatigue and dyspnoea on exertion, 
cutaneous lesions are slowly worsening; PET/CT scan 
picture is superimposable to that performed before the 
first Rituximab course. Diffusion of CO is further reduced 
(48%), while lung volumes and flow rates are stable. We 
are currently evaluating other therapeutic options.
Case 3
A 29 years old Caucasian woman was referred to our ILD 
outpatient clinic in April 2001; she had a 6  years history 
of pulmonary, cutaneous and ocular sarcoidosis, previ-
ously treated with two different lines of therapy: deflaza-
cort/methotrexate and deflazacort/azathioprine. Physical 
examination showed two violaceous-erythematous, non-
itchy, non-painful nodules over the knees. A fundus oculi 
examination detected residual atrophic granulomatous 
lesions, bilaterally. No hilar enlargement or interstitial lung 
disease were detected by a chest X-ray. High resolution 
computed tomography showed mild signs of diffuse inter-
stitial lung disease, with preserved respiratory volumes and 
DLCO at pulmonary function tests. Routine and immu-
nological blood test results were normal. We confirmed 
the ongoing therapy with deflazacort and azathioprine, 
started 10  months before. From March 2001 to August 
2006 the patient was lost to follow-up; during these years 
she underwent a progressive worsening of visual acuity. In 
August 2006, following the spontaneous attempt to taper 
her steroid therapy, a recurrence of severe cutaneous and 
ocular signs of disease brought the patient back to medi-
cal attention. Erythematous lesions were present on her 
knees at clinical examination; an ophthalmologic inves-
tigation showed bilateral retinal granulomatous disease 
and vasculitis, with more serious involvement of the right 
eye; chest HRCT and pulmonary function tests showed 
no worsening of lung disease; a complete blood tests 
panel was unremarkable. A 67-Ga scintigraphy underlined 
mild hypermetabolism in mediastinal nodes and lacrimal 
glands, bilaterally. A new treatment schedule including 
infliximab (5  mg/kg every 6  weeks for a total of 6 infu-
sions), methotrexate (15 mg/week) and deflazacort (3 mg/
die) achieved an almost complete clinical response; thus, a 
maintenance therapy was established with infliximab 5 mg/
kg every 8 weeks, methotrexate 7,5 mg/week and deflaza-
cort 1.5  mg/die. Steroids were completely withdrawn in 
September 2011. A chest CT in June 2011 showed marked 
reduction of the mediastinal lymphadenopathy.
In February 2012, during a follow-up visit, a further 
recurrence of ocular and cutaneous disease was detected. 
Thus, patient was shifted to adalimumab (40  mg every 
2  weeks) and prednisone (10  mg/die), with only par-
tial response. In October 2012 disease remission was 
achieved using the following schedule: cyclophos-
phamide (6 administrations of 500  mg, once weekly), 
mycophenolate mofetil (MM, 1000  mg/day) and pred-
nisone (12.5 mg/day). Unfortunately, eye and skin disease 
recurred early during the maintenance treatment with 
mycophenolate mofetil and prednisone. At that point, 
weekly rituximab treatment (6 administration of 375 mg/
m2, once weekly) was established. Since ocular disease 
was still progressing after the third infusion, cyclophos-
phamide was added to treatment (700  mg/administra-
tion for 5 administrations every 2 weeks). Unfortunately, 
disease progression was not arrested and patient com-
plained of complete sight loss of the right eye. Left eye 
examination showed vitreitis and active retinal granulo-
matosis and vasculitis. Given the high risk of complete 
sight loss and hypothesizing an activity of the anti-CD20 
treatment on those B cells sustaining the possible anti-
Infliximab antibody production, we made a new attempt 
of treatment with Infliximab. This attempt was surpris-
ingly successful, achieving in few weeks a complete 
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resolution of skin lesions and a satisfactory control of 
the ocular disease. Patient has currently no active disease 
under maintenance treatment with infliximab and a min-
imum dose of prednisone.
Conclusions
This small case series analyses the impact of Rituximab on 
three different settings of chronic and refractory sarcoido-
sis. Moreover, the administration schedule and dosage were 
not homogeneous, as well as the degree of effectiveness.
Patient 1 presented a chronic pulmonary sarcoidosis, 
with significant impairment of lung function; Rituxi-
mab was administered at a dosage of 375  mg/m2 every 
2 weeks for six times, arresting the disease progression. 
18  months after treatment clinical and radiological pic-
tures are still stable and this is the longest period of dis-
ease quiescence since diagnosis. Patient number 2 had a 
skin, lung and nodal disease, and the concomitant malig-
nancy strongly influenced the treatment approach for 
sarcoidosis. Administration schedule has been in turn 
influenced by patient’s needs for travelling, the dose was 
1  g per infusion monthly for three consecutive months; 
treatment was at first effective, but had to be repeated 
in 6  months due to early recurrence of symptoms and 
the second course was not as effective. The main goal 
achieved, in this case, was the withdrawal of steroids after 
years of treatment. The third patient presented an ocular 
disease with rapidly progressive sight loss; thus, a more 
dose-intensive lymphoma-like schedule was adopted 
(375  mg/m2/administration for six consecutive weeks) 
and cyclophosphamide was associated after 3 of 6 anti-
CD20 MAb infusions. In this patient rituximab was not 
effective on sarcoidosis activity, but we may hypothesize 
that anti-CD20 treatment was able to disrupt a possibly 
B-cell dependent resistance to infliximab, thus somehow 
contributing to the disease management.
In terms of safety, no one of the administration sched-
ules induced any infusion-related adverse events. 
Infusion pre-treatment included paracetamol, antihis-
tamines and dexamethasone, as standard practice, and 
patient 2 received a Lamivudine prophylaxis during 
the months of treatment and for 6 further months, due 
to serologic markers of anamnestic HBV infection. All 
patients presented a peripheral blood CD19 cells deple-
tion 3 months after the last anti-CD20 infusion. No lym-
phopenia was detected before or after treatment. No 
relative or absolute hypogammaglobulinemia occurred 
considering a mean of 1.2 years of follow-up after treat-
ment. In particular, all patients showed mild serum 
hypergammaglobulinemia before the first rituximab 
administration, that was no more detectable 3  months 
later. Gamma globulin levels never decreased below the 
reference value during follow-up; IgG, IgA and IgM levels 
were not significantly affected at any time point. Onset 
of therapeutic effects, if any, occurred within one month 
after the first administration.
In terms of efficacy, it is not possible to draw any defini-
tive conclusion on the basis of these three case reports 
that, indeed, represent a good sample of the previously 
published reports on this item. To our knowledge, there 
are only case reports, one retrospective study and a phase 
I/II open label trial currently available in literature, dis-
cussing the effectiveness of Rituximab in refractory sar-
coidosis (Table 1). Single case reports discussed successful 
use of anti-CD20 treatment in one case of neurosarcoido-
sis [11], one of sarcoidosis-associated neuromyelitis 
optica [12], one of lung, lymph-nodes and joint disease 
[15], one with peritoneal nodes involvement [13] and one 
more case of lymph node disease included in a case series 
of systemic autoimmune diseases [17]. The retrospective 
study included 4 patients with refractory ocular sarcoido-
sis, describing good results for three of them [14]. Finally, 
the prospective study, involving ten patients with chronic 
lung disease with moderate to severe pulmonary disease 
still symptomatic despite using a combination of corticos-
teroids and steroid sparing agents, showed inconsistent 
Table 1 Summary of reported case records and retrospective/prospective studies
References Main organ involvement Dose Outcome
Gottenberg et al. [17] Lymph nodes 4 × 375 mg/m2 Good
Belkhou et al. [15] Lymph nodes 2 × 1 g, every 2 weeks Good
Dasilva et al. [13] Lymph nodes, including peritoneal Two infusions, dose not specified Good
Bomprezzi et al. [11] CNS and skin 2 × 1 g, every 2 weeks, then 1 g every 
6 months for 2 years
Good
Lower et al. [14] Eye; 2 of 4 patients also had significant 
lung involvement
2 × 1 g, every 2 weeks, then 375 mg/
m2 every 4 or 8 weeks for a minimum 
of 24 months or 1 g every 4 weeks for 
10 months
Three responders of four patients
Sawaya et al. [12] Neuromyelitis optica and lymph nodes Single 1 g infusion Good
Sweiss et al. [16] Lung 2 × 1 g, every 2 weeks Seven full or partial responders of ten 
patients
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results within this small cohort of patients [16]. Thus, if 
single case reports point at rituximab as an effective treat-
ment option in refractory disease, when moving to case 
series the matter appears to be more controversial. Our 
case series is in line with this consideration, inasmuch we 
observed clear benefit only in one of three patients. This 
also suggests the need for identifying parameters that 
could be suggestive for a putative good response in sar-
coid patients with refractory disease.
Moreover, it is noteworthy that there is no agree-
ment on the administration schedule or dosage, with 
a split between the lymphoma-like approach (375  mg/
m2/administration every one or two weeks for 4–6 total 
administration) and a more Rheumatoid Arthritis-ori-
ented schedule (1 g every 2 weeks, for 2 or more admin-
istrations). Almost all patients have also been co-treated 
with different immune-suppressants and a long-term 
treatment with other drugs has been established after 
rituximab. The ophthalmologic case series also provides 
data on an anti-CD20 maintenance treatment, which 
is currently the standard of care in many hematologic 
malignancies, with a minimum duration of 10  months 
but different schedules. In addition, as expected in refrac-
tory diseases, the treatment history before rituximab of 
all the reported patients is extremely heterogeneous and 
it would be really hard to define which patients to include 
in a perspective study, also considering that last ATS/
ERS/WASOG guidelines on sarcoidosis are dated 2009.
Nevertheless, in consideration of some good results 
described in cases with poor prognosis, particularly in eye 
disease, all these open questions (patient selection, dose 
and administration schedule, co-treatment and main-
tenance treatment) would deserve an evidence based 
answer. Thus, there is a strong need for larger case series 
and prospective studies, in order to possibly design a mul-
ticentre prospective trial, the only way to get definitive 
answers and to optimize the use of health-care resources.
Finally, the rationale and mechanism of action of an 
anti-CD20 treatment in this T-cell mediated granuloma-
tous disease remains an intriguing topic, strongly related 
to what we still do not understand of etiology and patho-
genesis of this granulomatous disease.
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